Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies

Movement Disorders

Volumn 23, Issue 15, 2008, Pages 2248-2250

  Goldman, Jennifer G ^a   Goetz, Christopher G ^a   Brandabur, Melanie ^b   Sanfilippo, Michelle ^c   Stebbins, Glenn T ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b PARKINSON S INSTITUTE   (United States)

^c Alexian Neurosciences Institute   (United States)

Author keywords

Dementia with Lewy bodies; Levodopa; Parkinsonism; Psychosis

Indexed keywords

CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; LEVODOPA; MEMANTINE; NEUROLEPTIC AGENT; QUETIAPINE;

AGED; ARTICLE; CLINICAL ARTICLE; DEMENTIA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HALLUCINATION; HUMAN; LEWY BODY; MALE; MOTOR PERFORMANCE; PARKINSONISM; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; THOUGHT DISORDER; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; DOPAMINE AGONISTS; FEMALE; FOLLOW-UP STUDIES; HALLUCINATIONS; HUMANS; LEVODOPA; LEWY BODY DISEASE; MALE; MENTAL DISORDERS; MOVEMENT DISORDERS;

EID: 61449231824     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22322     Document Type: Article

References (15)

1. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-1872.
2. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
3. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005;66:633-637.
4. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 2003;18(Suppl 6):S72-S79.
5. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536.
6. Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005;76:1200-1203.
7. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004; 63:376-378.
8. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 1996;47:1148-1152.
9. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-678.
10. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
11. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004;62:201-207.
12. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
13. Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:1323-1328.
14. Ballard CG, O'Brien JT, Swann AG, Thompson P, Neill D, McKeith IG. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. J Clin Psychiatry 2001;62:46-49.
15. Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:484-500.